The current price of ZNTL is $1.71 — it has decreased by 2.84% since the previous close. Data as of Nov 5, 2026.
ZNTL is down 14.07% over the past week, down 38.49% over the past month and up 27.61% over the past year. The price is below its 200-day moving average of $3.44.
Of the 11 analysts covering Zentalis Pharmaceuticals, Inc., 8 rate it a buy and 3 rate it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Zentalis Pharmaceuticals, Inc. has a market capitalization of $121.73M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Zentalis Pharmaceuticals, Inc. posted a loss of $0.59 per share against an estimate of -$0.49, missing expectations by 20.41%. Upcoming reports are listed in the earnings calendar.
Zentalis Pharmaceuticals, Inc. has not paid any dividends over the past year.
In the latest trading session ZNTL moved between $1.63 and $1.82, a range of 11.11% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Zentalis Pharmaceuticals, Inc. shows a sell rating today and a strong sell rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Zentalis Pharmaceuticals, Inc. is sell. Technical ratings are indicators, not investment advice.
Over the past 52 weeks ZNTL has traded between $1.21 and $6.95. The current price is 75.40% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.